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Introduction
Plantar fasciitis (PF) is mainly a clinical diagnosis characterised by medial heel pain, which is often worse with the first few steps in the morning.  It is commoner in the obese, in those standing for prolonged periods at work, and in those whose jobs involve walking on hard surfaces [1, 2].  It remains the commonest cause of plantar heel pain [3].  

The diagnosis is mainly based on the patients’ history and clinical findings.  Further investigations are seldom required [4], but may be necessary to rule out other underlying pathologies such as nerve entrapment, stress fracture, tumour or infection and systemic underlying conditions such as rheumatoid arthritis, and some sero-negative spondyloarthropathies such as ankylosing spondylitis and Reiter syndrome.

In over 80% of cases, symptoms can be resolved with simple non-operative measures of eccentric stretching exercises to the Achilles tendon and plantar fascia, cushioned insoles or orthotics to correct biomechanical factors, night splints, activity modification and use of simple analgesics [5].

In the minority of patients who develop intractable plantar fasciitis, other options available include cortico-steroid injections and extracorporeal shock wave therapy [6].  Surgical release of the fascia can also be considered, but results have been variable in efficacy [7, 8]. 

Biologic treatments such as platelet-rich plasma (PRP) have started to gain popularity in recent years, for a wide variety of orthopaedic conditions, though as yet there are few robust trials [9].  PRP is derived by centrifuging whole blood and has a platelet concentration higher than that of whole blood.  These platelets produce granules that release growth factors that initiate and promote natural tissue healing.  Studies of its use in chronic lateral epicondylitis of the elbow show some encouraging results [10, 11, 12].  Other studies have looked at its use in augmentation of operative repair of the Achilles tendon [13], and use in the treatment of chronic patellar tendinopathy [14].

The underlying condition that causes plantar fasciopathy is a degenerative tissue condition that occurs near the site of the origin of the plantar fascia at the medial tuberosity of the calcaneus.  To date, we have been able to find only one report in the orthopaedic literature evaluating the efficacy of PRP in the treatment of plantar fasciitis.  Barrett and Erredge [15] in their study of 9 patients who underwent PRP injection for plantar fasciitis found a significant improvement in symptoms, which was maintained at one year’s follow up. 
Patients and methods
Patients presenting to the Wrightington Hospital with intractable plantar fasciitis, which had not responded to cushioned insoles, a full course of eccentric stretching exercises and at least one previous cortico-steroid injection, were offered PRP injection therapy.  All patients had symptoms for at least 12 months.  In addition to pre-operative assessment, patients were reviewed in the Foot and Ankle clinic at three and six months following injection.

All patients were assessed with the Roles-Maudsley (RM) Score, the Visual Analogue Score for pain and the American Orthopaedic Foot and Ankle Society (AOFAS) Ankle and Hindfoot score.  Patients were asked at the six month review whether they would have the procedure again.  Complications of the procedure were also documented.

Platelet-rich plasma was harvested with the use of GPSIII system (Biomet Biologics, Warsaw, IN).  Twenty seven millilitres (mls) of blood was withdrawn from the patient and added to 3mls of sodium citrate (anticoagulant).  This was placed in the centrifuge machine and spun for 15 minutes at 3200 revolutions per minute.  The plasma portion was discarded.  Since an acidic anticoagulant is introduced to the whole blood used to produce the platelet concentrate, the PRP portion harvested was buffered with 8.4% sodium bicarbonate, to increase the pH back to normal physiological levels.  From the initial blood harvest, between 2.5 and 3.5 mls of buffered PRP was obtained and injected under aseptic technique directly into the area of maximal tenderness at the heel, via a peppering technique.  Three patients who underwent a bilateral injection at the same sitting, the volume was divided between the two heels.  All patients were advised to continue with their eccentric stretching programme and the cushioned insoles following the injection.  





Full sets of data was available on 47 heels (41 patients).  As incomplete data for a patient, arising from lack of compliance with the research protocol, led by default to exclusion from the inferential statistical analyses, sample details are only reported here for these 41 patients for the sake of consistency. Six of these 41 patients had bilateral injections – three of these were performed at the same sitting, with the other three patients having the injections performed on separate occasions.  There were 14 male patients and 27 female patients with a mean age of 51 years (range 25-79).  The left side was injected in 17 patients, the right side in 18, and bilateral injection in 6 patients. 

Assessment measures
Table 1 summarises the scores obtained from the RM instrument, the VAS for pain, and the AOFAS ankle and hindfoot score.  
Insert Table 1 about here

The RM instrument showed a lower score at both follow-up points compared to pre-injection scores, indicating an improvement in the patients. The main effect across these three measurement points was highly significant (χ 2 [2, N = 46] = 55.635, p < .001). The pre-injection ratings were significantly higher than ratings at the 3 month follow up with 33 ratings in this direction (mean ranking = 17.83), 1 rating in the opposite direction (mean ranking = 6.5), and 12 tied ratings (p < .001, two tailed). Similarly, the pre-injection ratings were significantly higher than the 6 month follow up ratings with 33 ratings in this direction (mean ranking = 17.0), no ratings in the opposite direction, and 13 tied ratings (p < .001, two tailed).  

VAS scores were lower at both follow-up points than the pre-injection scores, showing less pain being reported by patients. The main effect across these three measurement points was highly significant (χ 2 [2, N = 46] = 46.177, p < .001). The pre-injection ratings were significantly higher than ratings at the 3 month follow up with 33 ratings in this direction (mean ranking = 19.29), 3 ratings in the opposite direction (mean ranking = 9.83), and 10 tied ratings (p < .001, two tailed). The pre-injection ratings were also significantly higher than the 6 month follow up ratings with 33 ratings in this direction (mean ranking = 18.71), 2 ratings in the opposite direction (mean ranking = 6.25), and 11 tied ratings (p < .001, two tailed).  

The increase in AOFAS ratings across the three measurement points showed an improvement in the condition of patients. As sphericity could not be assumed for the within-participants ANOVA (Mauchley’s W = .505, approximate χ 2 [2] = 29.349, p < .001), the Greenhouse-Geisser F value was taken. This showed a highly significant main effect across the three measurement points (F (1.338, 58.876) = 36.982, p < .001, ƞp2 = .457). The post hoc comparisons showed that the pre-injection ratings were significantly lower than ratings at both the 3 month follow up (p < .001, two tailed) and the 6 month follow up (p < .001, two-tailed), respectively.

Patients were asked at the six month stage whether or not they would have the procedure again.  28 patients (64%) were very satisfied with the clinical improvement and would have the injection again.  3 patients had bilateral simultaneous injections, which unfortunately did not seem to work, and this technique was therefore abandoned during the study period.  3 further patients who had bilateral injections, performed on separate occasions, reported good results and would have the injection again.

Twenty-two patients (50%) were found to have complete or almost complete resolution of symptoms (AOFAS 90 and above), and a further 8 patients (18%) had an AOFAS score above 80.  All of these patients attributed their improvement to the PRP injection.  One patient was found to have tarsal tunnel syndrome, which improved following surgical decompression.
Discussion
Patients presenting to the Foot and Ankle clinic with intractable plantar fasciitis present a particular challenge.  It can be a chronic debilitating condition, and may not respond to traditional methods of treatment [17,18].  These newer biologic treatments aim to initiate and promote natural healing and allow for direct repair of the damaged tissue, without the attendant risks of surgery.  Studies suggest the Biomet Biologics GPS III system gives a four to five fold concentrate platelets over patients own blood [16].  As platelets contain granules and growth factors, which promote and initiate a healing response, it is hypothesised that by concentrating them, and injecting them focally to the site of diseased tissue, it will initiate and induce a natural healing response.

This is the largest study to date looking at the efficacy of treatment of PRP in plantar fasciopathy, with the previously published pilot study of Barrett and Erredge [15] only looking at 9 patients.  We found this procedure to be well tolerated by patients.  We did not utilise local anaesthetic, and the injections were performed by injecting directly into the area of maximal tenderness.  Whilst we did not use ultrasound (USS) guidance for the injection, we accept arguably this may allow for a more accurate placement of the PRP and could be considered.  However, a RCT by Kane et al [19] showed no advantage of USS guidance over direct palpation guidance of the most tender area, when steroid was injected for plantar fasciitis. 

This was a safe procedure with no reported complications in our patients on review.  All patients who improved felt that this was directly related to the PRP injection, although all patients were also encouraged to continue with the gel heel cups and stretching exercises.  Improvement was noted within the first three months from the injection.  There was no further significant improvement in symptoms between three and six months, but equally no deterioration or relapse, with efficacy maintained for the full six months of the study duration.

We found that the 3 patients who underwent bilateral PF injections at the same sitting did not improve.  This may have been related to the reduced volume of PRP that was injected into each heel (only 1.5 mls to each heel).  Subsequent bilateral injections have been performed at separate intervals, and the full amount of PRP (3mls) has been injected into each heel, with success.

One patient was found to have tarsal tunnel syndrome and this improved following surgical decompression.  In intractable cases, it is important to rule out other conditions which can mimic plantar fasciitis, such as tarsal tunnel syndrome and stress fractures.  Additional investigations may be warranted such as MRI scanning or nerve conduction testing.

The authors recognise the failings in this study, particularly in view of the fact it has no control arm.  However the authors feel these results show some promise for a new technique, which now warrants further study and investigation with a randomised controlled trial.  
Conclusions
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	Table 1. Summary of assessment scores for patients 
Measure	Pre-injection	3 months follow up	6 months follow up
	Mean or median	Measure of spread	Mean or median	Measure of spread	Mean or median	Measure of spread
Roles-Maudsley	Median = 4	Inter-quartile range = 0.0	Median = 2	Inter-quartile range = 2.0	Median =2	Inter-quartile range = 1.0
Visual analogue scale for pain	Mean = 7.9	SD = 1.4	Mean = 5.1	SD = 3.0	Mean = 4.7	SD = 3.2
AOFAS	Mean = 62.3	SD = 13.2	Mean = 77.9	SD = 16.6	Mean = 80.5	SD = 16.6




